-
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the…
-
STARMED Receives FDA 510(k) Clearance for a Benign Thyroid Nodule Ablation Indication
SEOUL, South Korea, July 1, 2026 /PRNewswire/ — STARMED, a medical device company specialising in minimally invasive treatment technologies, has announced that it has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for a thyroid-specific indication (510(k) number: K252833). The clearance took effect on 26 May 2026. The company’s system may now…
-
Jelly Force Male Enhancement Gummies Release Latest Formula for Men: JellyForce Unique Ingredient Profile Report
Pinellas Park, FL, July 02, 2026 (GLOBE NEWSWIRE) — These statements have not been evaluated by the Food and Drug Administration. JellyForce is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use, especially if currently taking prescription medications. JellyForce is a gummy dietary supplement formulated for men,…
-
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
June 30, 2026 20:38 ET | Source: Mesoblast Limited NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a…
-
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and…
-
JellyFil Publishes Updated 2026 Product Information for Its Premium Gummy Dietary Supplement, Including Full Ingredient List, Pricing, Refund Policy, and Customer Service Details
Largo, FL, June 20, 2026 (GLOBE NEWSWIRE) — These statements have not been evaluated by the U.S. Food and Drug Administration. JellyFil is not intended to diagnose, treat, cure, or prevent any disease. Consumers should consult a qualified healthcare professional before using any dietary supplement, particularly if currently taking prescription medications or managing existing health…
-
BreathEaseX Publishes Updated 2026 Product Information for Its Oral Spray Dietary Supplement, Including Full Ingredient List, Pricing, Refund Policy, and Customer Service Details
AURORA, CO, June 19, 2026 (GLOBE NEWSWIRE) — These statements have not been evaluated by the U.S. Food and Drug Administration. BreathEaseX is not intended to diagnose, treat, cure, or prevent any disease. Consumers should consult a qualified healthcare professional before using any dietary supplement, particularly if currently taking prescription medications or managing existing health…
-
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
Press Release Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470 Exclusive licensee for China, Ocumension, received positive pre-submission regulatory feedback from the Chinese Center for Drug Evaluation (CDE) for NCX 470 Based on this feedback, Ocumension intends to proceed with the New Drug Application (NDA) submission in China Submission…
-
Morepen Labs' Facility Clears USFDA Inspection with NIL Adverse Observation for the Record Fourth Consecutive Time
Company sets a benchmark again in pharmaceutical excellence reinforcing its global leadership in quality and regulatory compliance Gurugram, Haryana, India Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced the successful completion of a USFDA (United States Food and Drug Administration) inspection at its Masulakhanna (Himachal) facility, with Zero adverse observations (No Form 483 issued…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
